Focus area
Rare Disease Investment Firms
The RaiseHunt database lists 30 Rare Disease investment firms: 28 of them list a portfolio, 194 known investments between them and 79 people at those firms have a profile here. Most list Seed and Series A among the rounds they take part in; the largest concentrations are in Boston, New York and Durham.
- 30
- Investment firms
- 28
- With a known portfolio
- 194
- Known investments
- 79
- People with a profile
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
30 Rare Disease investment firms
Showing 1-20
| Firm | Location | Type | Markets | Contact | Actions |
|---|---|---|---|---|---|
PC Pappas Capital (Pappas Ventures) | Durham, United States | Venture capital | Healthcare | View fund | |
AC Agent Capital | Boston, United States | Venture capital | AIHealthcare | View fund | |
KP Kurma Partners | Paris, France | Venture capital | AIHealthcare | View fund | |
AC Aisling Capital | New York, United States | Venture capital | Healthcare | View fund | |
CZ Chan Zuckerberg Initiative | Palo Alto, United States | Family Office | ClimateEducation | View fund | |
GG Gordonmd Global Investments | New York, United States | Private equity | Healthcare | View fund | |
OF Omega Funds | Boston, United States | Private equityVenture capital | Healthcare | View fund | |
CI Catalytic Impact Foundation | New York City, United States | Venture capital | AIHealthcare | View fund | |
NN Novo Nordisk | Copenhagen, Denmark | Corporate VC | Healthcare | View fund | |
T Takeda | Boston, United States | Corporate VC | Healthcare | View fund | |
3F 3B Future Health Fund I & II | Monte-Carlo, Monaco | Venture capital | Healthcare | View fund | |
CV CureDuchenne Ventures | Brookline, United States | Private equity | Healthcare | View fund | |
PB Pureos Bioventures | Zürich, Switzerland | Venture capital | Healthcare | View fund | |
CF Cystic Fibrosis Foundation | Corporate VC | Healthcare | View fund | ||
CV Claris Ventures | Turin, Italy | Venture capital | HardwareHealthcare | View fund | |
FF Foundation Fighting Blindness | Government-backed | Healthcare | View fund | ||
KD Kineticos Disruptor Fund | Raleigh, United States | Venture capital | AIHealthcare | View fund | |
MD Muscular Dystrophy Association | Family Office | Healthcare | View fund | ||
ST Sarepta Therapeutics | Corporate VC | Healthcare | View fund | ||
HD Harrington Discovery Institute at University Hospitals | Cincinnati, United States | Accelerator | Healthcare | View fund |
Frequently asked questions
How many Rare Disease investment firms are on RaiseHunt?
RaiseHunt lists 30 Rare Disease investment firms.
How many of them have a known portfolio?
28 of the 30 firms list at least one portfolio company, 194 known investments between them.
Who can I reach at these firms?
79 people working at them have a profile here, each with their role at the firm and whether an email address is on file.
Where are most Rare Disease investment firms based?
The largest concentrations are in Boston, New York and Durham.
What rounds do Rare Disease investment firms take part in?
Most list Seed and Series A among their stages.
How do I contact Rare Disease investment firms?
Every firm page shows whether an email address is on file, and the named contacts at that firm. The addresses themselves, along with AI matching and outreach, are in the RaiseHunt app.
Is the list of Rare Disease investment firms free to browse?
Yes. The directory and every firm page are free to read. Matching your own startup against them requires an account.
Do Rare Disease funds only back Rare Disease companies?
No. A focus area is a signal of interest, not a restriction. Firms usually list several, and the useful question is whether the existing portfolio looks like the kind of company you are building.
How many firms should I approach?
Far more than feels comfortable. Response rates on cold outreach are low even when the fit is good, so a short list of perfect names tends to stall. Build a long list, sort it by how well each firm matches what you are building, and work down it in batches rather than sending everything at once.
What should I have ready before reaching out to a firm?
A short deck, a one-paragraph description of what you do and who it is for, and a clear number for how much you are raising. Partners read the first two lines before they decide whether to open the deck, so those lines matter more than the rest of the document.
Does a warm introduction still matter with a fund?
It helps, mostly because it moves your email out of a crowded inbox. It is not a requirement. A cold message that shows you understand what the firm has already backed, and why your company fits that pattern, gets read more often than a vague introduction from a distant contact.
How does a decision get made inside a firm?
Usually by a group rather than by the person you first spoke to. One partner sponsors the deal internally and takes it to the rest, which is why the process runs longer than an angel conversation and why a single enthusiastic meeting is not yet a commitment.
Does the location of a firm matter?
Less than it used to. Plenty of firms back companies outside their own city, and remote first meetings are normal. Being nearby helps with introductions and later conversations, but it is rarely the thing that decides an investment.
Data: RaiseHunt investor dataset · Snapshot 27 August 2026 · How this data is built · Report a correction or request removal